Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program

Main Article Content

Neil Korman
Thierry Passeron
Kenneth Gordon
Yukari Okubo
Jerry Bagel
Howard Sofen
Richard Warren
Neal Bhatia
Lynda Spelman
Kevin Winthrop
Lauren Hippeli
Renata Kisa
Subhashis Banerjee
Diamant Thaçi

Keywords

deucravacitinib, psoriasis, POETYK

Abstract

N/A

References

1. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736.

2. SOTYKTUTM (deucravacitinib) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; September 2022.

3. Papp K, et al. N Engl J Med. 2018;379:1313-1321.

4. Winthrop KL. Nat Rev Rheumatol. 2017;13:234-243.

5. Armstrong A, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02256-3. doi: 10.1016/j.jaad.2022.07.002. Online ahead of print.

6. Strober B, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02643-3. doi: 10.1016/j.jaad.2022.08.061. Online ahead of print.

7. Thaçi D, et al. Presented at the European Academy of Dermatology and Venereology (EADV) 30th Congress; September 29—October 2, 2021.

8. Warren RB, et al. Presented at the European Academy of Dermatology and Venereology (EADV) Spring Symposium; 12—14 May 2022; Ljubljana, Slovenia.

9. Wrobleski ST, et al. J Med Chem. 2019;62:8973-8995.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>